You just read:

Tibotec to Present Final Safety and Efficacy Results From Phase 2b PILLAR Study of Once-Daily TMC435 in Late-Breaker at AASLD

News provided by

Tibotec Pharmaceuticals

Nov 05, 2011, 09:05 ET